Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan 430060, People's Republic of China.
Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan 430060, People's Republic of China.
Tissue Cell. 2023 Oct;84:102198. doi: 10.1016/j.tice.2023.102198. Epub 2023 Aug 18.
Chronic liver disease inevitably progresses to liver cirrhosis, significantly compromising patients' overall survival and quality of life. However, a glimmer of hope emerges with the emergence of mesenchymal stem cells, possessing remarkable abilities for self-renewal, differentiation, and immunomodulation. Leveraging their potential, MSCs have become a focal point in both basic and clinical trials, offering a promising therapeutic avenue to impede fibrosis progression and enhance the life expectancy of individuals battling hepatic cirrhosis. This comprehensive review serves to shed light on the origin of MSCs, the intricate mechanisms underlying cirrhosis treatment, and the cutting-edge advancements in basic and clinical research surrounding MSC-based therapies for liver cirrhosis patients.
慢性肝病不可避免地会发展为肝硬化，显著降低患者的整体生存率和生活质量。然而，间充质干细胞的出现带来了一线希望，其具有显著的自我更新、分化和免疫调节能力。利用其潜力，间充质干细胞已成为基础和临床试验的焦点，为阻止纤维化进展和提高肝硬化患者的预期寿命提供了有前景的治疗途径。本综述旨在阐明间充质干细胞的起源、肝硬化治疗的复杂机制，以及基于间充质干细胞治疗肝硬化患者的基础和临床研究的最新进展。
